Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
- Sponsor
- Japan Multinational Trial Organization
- Study ID
- NCT00104793
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- carboplatin — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving irinotecan together with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin works in treating patients with newly diagnosed extensive-stage small cell lung cancer.
Key Dates
- Start date
- Jun 30, 2003
- Status verified
- Oct 2007
- Primary completion
- Feb 28, 2007
- Completion
- Nov 30, 2008
Study Design
- Enrollment
- 55 participants (estimated)
- Primary purpose
- TREATMENT
Primary Outcome Measure
Response
Related Studies
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Detection of Genetic Markers of Lung CancerRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York